SCHEMBL164503

SCHEMBL164503

Nc1ccc(S(=O)(=O)Nc2cccc3ccccc23)cc1

nearest known ligand 0.76

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RECQL P46063 1/20 0.76
KMT2A Q03164 6/20 0.70
MEN1 O00255 4/20 0.70
ALDH1A1 P00352 2/20 0.70
MAPT P10636 1/20 0.70
HTR6 P50406 3/20 0.61
TDP1 Q9NUW8 1/20 0.61
CA1 P00915 1/20 0.60
CA2 P00918 1/20 0.60
CA9 Q16790 1/20 0.60
LMNA P02545 1/20 0.59
HTT P42858 1/20 0.59
KEAP1 Q14145 4/20 0.56
NFE2L2 Q16236 2/20 0.53
ALOX12 P18054 1/20 0.51
CHEK1 O14757 1/20 0.50
CDK8 P49336 1/20 0.50
NEK2 P51955 1/20 0.50
LIMK1 P53667 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1428546 0.86 RECQL (1.00) RECQLKMT2AMEN1ALDH1A1MAPT
SCHEMBL29962236 0.86 KMT2A (0.57) RECQLKMT2AMEN1ALDH1A1MAPT
SCHEMBL7573136 0.84 KEAP1 (0.76) RECQLKMT2AMEN1ALDH1A1MAPT
SCHEMBL7578880 0.84 KEAP1 (0.76) RECQLKMT2AMEN1ALDH1A1MAPT
SCHEMBL7537943 0.84 RECQL (0.76) RECQLKMT2AMEN1ALDH1A1MAPT
SCHEMBL7572140 0.83 RECQL (0.69) RECQLKMT2AMEN1ALDH1A1MAPT
SCHEMBL11860610 0.82 KMT2A (0.52) RECQLKMT2AMEN1ALDH1A1MAPT
SCHEMBL7536143 0.81 RECQL (0.71) RECQLKMT2AMEN1ALDH1A1MAPT
SCHEMBL9942077 0.81 RECQL (0.71) RECQLKMT2AMEN1ALDH1A1MAPT
SCHEMBL27499581 0.81 RECQL (0.76) RECQLKMT2AMEN1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11279687-B2 Compounds and compositions for the inhibition of NAMPT VALO HEALTH, INC. (US) 2022-03-22 US disclosed
US-20200283403-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT Valo Health, LLC 2020-09-10 US disclosed
US-20200283403-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT Valo Health, LLC 2020-09-10 US disclosed
US-10647695-B2 Compounds and compositions for the inhibition of NAMPT FORMA TM, LLC (US) 2020-05-12 US disclosed
US-10647695-B2 Compounds and compositions for the inhibition of NAMPT FORMA TM, LLC (US) 2020-05-12 US disclosed
US-20190270721-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT Valo Health, LLC 2019-09-05 US disclosed
US-20190270721-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT Valo Health, LLC 2019-09-05 US disclosed
US-10329275-B2 Compounds and compositions for the inhibition of NAMPT FORMA TM, LLC (US) 2019-06-25 US disclosed
US-10329275-B2 Compounds and compositions for the inhibition of NAMPT FORMA TM, LLC (US) 2019-06-25 US disclosed
US-20180291000-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT VALO HEALTH, INC. 2018-10-11 US disclosed
US-20130273034-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT VALO EARLY DISCOVERY, INC. 2013-10-17 US disclosed
EP-2611777-A1 4- { [ ( PYRIDIN- 3 - YL -METHYL) AMINOCARBONYL]AMINO} BENZENE - SULFONE DERIVATIVES AS NAMPT INHIBITORS FOR THERAPY OF DISEASES SUCH AS CANCER Forma TM, LLC. (US) 2013-07-10 EP disclosed
WO-2012031196-A9 4- { [ ( PYRIDIN- 3 - YL -METHYL) AMINOCARBONYL] AMINO} BENZENE - SULFONE DERIVATIVES AS NAMPT INHIBITORS FOR THERAPY OF DISEASES SUCH AS CANCER FORMA TM, LLC (US) 2013-06-13 WO disclosed
WO-2012031196-A1 4- { [ ( PYRIDIN- 3 - YL -METHYL) AMINOCARBONYL] AMINO} BENZENE - SULFONE DERIVATIVES AS NAMPT INHIBITORS FOR THERAPY OF DISEASES SUCH AS CANCER FORMA THERAPEUTICS, INC. (US) 2012-03-08 WO disclosed
WO-2012031196-A1 4- { [ ( PYRIDIN- 3 - YL -METHYL) AMINOCARBONYL] AMINO} BENZENE - SULFONE DERIVATIVES AS NAMPT INHIBITORS FOR THERAPY OF DISEASES SUCH AS CANCER FORMA THERAPEUTICS, INC. (US) 2012-03-08 WO disclosed
EP-0482508-B1 Biscationic azo dyes and their intermediates BASF AG (DE) 1995-07-12 EP disclosed
US-5424404-A Colorfastness, discoloration inhibition, red and yellow color; coloring paper, leather, printing on polymeric material BASF AKTIENGESELLSCHAFT (DE) 1995-06-13 US disclosed
EP-0482508-A1 Biscationic azo dyes and their intermediates BASF Aktiengesellschaft (DE) 1992-04-29 EP disclosed
US-4136033-A DIAZO COUPLERS SANDOZ LTD. (CH) 1979-01-23 US disclosed
US-3769075-A PROCESS FOR PROTECTING A SUBSTRATE WITH AN N{11 ARYL SUBSTITUTED ARYLSULFONAMIDE INTUMESCENT AGENT CITIES SERVICE CO 1973-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10647695-B2 Compounds and compositions for the inhibition of NAMPT NAMPT, NNT, NQO1 RECQL 2720/4885KMT2A 659/4885MEN1 438/4885
US-20200283403-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT NAMPT, HAMP, NQO1 RECQL 3115/4885KMT2A 1299/4885MEN1 468/4885
US-11279687-B2 Compounds and compositions for the inhibition of NAMPT NAMPT, NNT, NQO1 RECQL 2720/4885KMT2A 659/4885MEN1 438/4885
US-20180291000-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT NAMPT, HAMP, NQO1 RECQL 3115/4885KMT2A 1299/4885MEN1 468/4885
US-10329275-B2 Compounds and compositions for the inhibition of NAMPT NAMPT, NNT, NQO1 RECQL 2720/4885KMT2A 659/4885MEN1 438/4885
US-20190270721-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT NAMPT, HAMP, NQO1 RECQL 3115/4885KMT2A 1299/4885MEN1 468/4885
US-20130273034-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT NAMPT, NNMT, NQO1 RECQL 3283/4885KMT2A 1615/4885MEN1 582/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.